Curis to Release Fourth Quarter and Year End 2015 Financial Results and Hold Conference Call on February 29, 2016
LEXINGTON, Mass., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will release its fourth quarter and year-end 2015 financial results on Monday, February 29, 2016, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EST to review its various pipeline programs, including CUDC-907, a dual HDAC/ PI3K inhibitor, and CA-170, an oral small molecule antagonist of PD-L1/VISTA under collaboration with Aurigene, and its partnered program, Erivedge® (vismodegib). The Company's management will also review its financial results as of and for the fourth quarter and year ended December 31, 2015.
To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 8:30 a.m. EST. The conference ID number is 46140545. The conference call can also be accessed on the Curis website at www.curis.com within the Investors section.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, a dual HDAC and PI3K inhibitor that is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 pathway/ VISTA, including PD-L1/VISTA antagonist CA-170, as well as to molecules designed to inhibit IRAK4, including CA-4948. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma and are further developing Erivedge® in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis' website at www.curis.com.
For More Information: Mani Mohindru, Ph.D. Senior Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 firstname.lastname@example.org Media Contact: David Schull Russo Partners 212-845-4271 email@example.com